YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Roche to buy U.S. biotech firm InterMune for $8.3B

Posted online
Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc. for $8.3 billion in cash, helping the world's leading maker of cancer drugs expand into the treatment of rare or incurable diseases.

Swiss drugmaker Roche is paying $74 per share, representing a premium of 38 percent to the Aug. 22 closing price.

According to Reuters, the InterMune deal brings Roche a promising new drug, pirfenidone, for treating a progressive and ultimately fatal scarring condition of the lungs.

Read more from Reuters.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences